SYNTHESIS AND BIOLOGICAL-ACTIVITY OF THIAZOLYLINDOLEQUINONES, ANALOGS OF THE NATURAL PRODUCT BE-10988

被引:26
作者
MOODY, CJ
SWANN, E
HOULBROOK, S
STEPHENS, MA
STRATFORD, IJ
机构
[1] CHURCHILL HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,OXFORD OX3 7LJ,ENGLAND
[2] MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND
基金
英国医学研究理事会;
关键词
D O I
10.1021/jm00006a024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A number of analogues of the naturally occurring thiazolylindolequinone BE 10988, a reported potent inhibitor of topoisomerase II, have been prepared and evaluated. The compounds were synthesized from 4-(benzyloxy)-S-methoxy-1-methylindole by appropriate substitution at the indole 3-position followed by standard thiazole ring-forming reactions. The toxicity of these potentially bioreductively activated indolequinones was measured in Chinese hamster V79 cells under aerobic and hypoxic conditions. In addition, toxicity was measured in a human breast cancer cell line that shows amplification of the topo II alpha gene and hypersensitivity to known topo II inhibitors such as mAMSA and mitoxantrone. Using a DNA decatenation assay, a comparison was also made of the inhibitory effects of BE 10988 and mitoxantrone on topo II activity.
引用
收藏
页码:1039 / 1043
页数:5
相关论文
共 23 条
  • [11] DIFFERENTIAL MODULATION OF DOXORUBICIN TOXICITY TO MULTIDRUG AND INTRINSICALLY DRUG-RESISTANT CELL-LINES BY ANTIESTROGENS AND THEIR MAJOR METABOLITES
    KIRK, J
    HOULBROOK, S
    STUART, NSA
    STRATFORD, IJ
    HARRIS, AL
    CARMICHAEL, J
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (06) : 1189 - 1195
  • [12] SYNTHESIS OF THE TOPOISOMERASE-II INHIBITOR BE-10988
    MOODY, CJ
    SWANN, E
    [J]. TETRAHEDRON LETTERS, 1993, 34 (12) : 1987 - 1988
  • [13] SYNTHESIS OF THE NATURALLY-OCCURRING INDOLEQUINONE BE-10988, AN INHIBITOR OF TOPOISOMERASE-2
    MOODY, CJ
    SWANN, E
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1993, (21): : 2561 - 2565
  • [14] CYCLOPROPAMITOSENES - NOVEL BIOREDUCTIVE ANTICANCER AGENTS - MECHANISM OF ACTION AND ENZYMATIC REDUCTION
    MOODY, CJ
    OSULLIVAN, N
    STRATFORD, IJ
    STEPHENS, MA
    WORKMAN, P
    BAILEY, SM
    LEWIS, A
    [J]. ANTI-CANCER DRUGS, 1994, 5 (03) : 367 - 372
  • [15] A NEW TOPOISOMERASE-II INHIBITOR, BE-10988, PRODUCED BY A STREPTOMYCETE .1. TAXONOMY, FERMENTATION, ISOLATION AND CHARACTERIZATION
    OKA, H
    YOSHINARI, T
    MURAI, T
    KAWAMURA, K
    SATOH, F
    FUNAISHI, K
    OKURA, A
    SUDA, H
    OKANISHI, M
    SHIZURI, Y
    [J]. JOURNAL OF ANTIBIOTICS, 1991, 44 (05) : 486 - 491
  • [16] NOVEL CYTOTOXIC TOPOISOMERASE-II INHIBITING PYRROLOIMINOQUINONES FROM FIJIAN SPONGES OF THE GENUS ZYZZYA
    RADISKY, DC
    RADISKY, ES
    BARROWS, LR
    COPP, BR
    KRAMER, RA
    IRELAND, CM
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1993, 115 (05) : 1632 - 1638
  • [17] ROBSON CN, 1987, CANCER RES, V47, P1560
  • [18] DNA TOPOISOMERASES AS TARGETS FOR CANCER-THERAPY
    ROSS, WE
    [J]. BIOCHEMICAL PHARMACOLOGY, 1985, 34 (24) : 4191 - 4195
  • [19] SMITH K, 1993, ONCOGENE, V8, P933
  • [20] THE DIFFERENTIAL HYPOXIC CYTO-TOXICITY OF BIOREDUCTIVE AGENTS DETERMINED INVITRO BY THE MTT ASSAY
    STRATFORD, IJ
    STEPHENS, MA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (04): : 973 - 976